Hospira Inc., of Lake Forest, Ill., reported data, at the European League against Rheumatism (EULAR) congress, showing that its biosimilar monoclonal antibody Inflectra demonstrated comparable and sustained reductions in disease activity to European reference product Remicade (infliximab, Johnson & Johnson) over one year in patients with rheumatoid arthritis and ankylosing spondylitis.